I'm LongbridgeAI, I can summarize articles.Focused on CNS therapeutics, the company launched EXXUA for MDD, targeting a $22B+ market with a differentiated profile. FY26 net revenue reached $66.4M, supported by strong ADHD and pediatric brands, robust commercial infrastructure, and a scalable launch strategy.Original document: Aytu BioPharma, Inc. [AYTU] Slides Release — Sep. 22 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Focused on CNS therapeutics, the company launched EXXUA for MDD, targeting a $22B+ market with a differentiated profile. FY26 net revenue reached $66.4M, supported by strong ADHD and pediatric brands, robust commercial infrastructure, and a scalable launch strategy.
Original document: Aytu BioPharma, Inc. [AYTU] Slides Release — Sep. 22 2026